BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Zuellig Pharma strengthens clinical sourcing capabilities in China through strategic acquisition

November 4, 2026 | News

The acquisition of newly licensed Hangzhou facility establishes robust local sourcing capabilities to accelerate and support clinical trials across China



Zuellig Pharma, a leading healthcare solutions company in Asia, has announced the strategic acquisition of a specialised clinical supply facility in Hangzhou, China, strengthening its clinical sourcing capabilities to better support domestic and international clinical trials.

The Hangzhou facility holds a Drug Distribution License (DDL), enabling Zuellig Pharma to provide local clinical sourcing of comparator drugs and concomitant medications in China. This strengthens Zuellig Pharma's ability to offer compliant, in-market sourcing solutions while streamlining billing processes and creating opportunities for value-added tax (VAT) savings for clinical trial sponsors.

Strategically located in the heart of Yangtze River Delta's biopharmaceutical innovation corridor, the Hangzhou facility complements and seamlessly connects to Zuellig Pharma's existing Beijing depot and its global network of over 45 clinical depots. To safeguard product integrity, the new facility is equipped with advanced cold-chain capabilities and precision-controlled environments across temperature-controlled capacities ranging from 15–25°C, 2–8°C, and -20°C.

Zuellig Pharma's Clinical Trial Support business serves as a trusted clinical logistics and sourcing partner to 29 of the world's top 50 pharmaceutical companies and 18 of the top 50 global Contract Research Organizations, delivering integrated end-to-end clinical supply chain solutions worldwide.